Pharmacoepidemiological study of treatment managment in patients with type 2 diabetes mellitus in Omsk

Treatment management strategy for patients with type 2 diabetes mellitus (2DM) includes glycaemic control, blood pressure and lipid metabolism parameters. Pharmacoepidemiological monitoring allows evaluating the compliance of the treatment really provided for 2DM with the present guidelines.

Aim.

To study the actual implementation of pharmaceuticals control for patientswith type 2 diabetes, residents of the city of Omsk, in 2013—2014.

Material and methods. 

It was a retrospective open cohort study based on the fragment data of the Regional Diabetes Register including 33 187 cases with prescription of oral antidiabetic drugs (OAD), 285 patient cases and OAD consumption and expenses data in 2014. The prescribed daily dose (PDD) was determined. It was assessed the efficiency and effectiveness of antihypertensive and lipid-lowering therapy.

Results.

In Omsk metformin prevails in OAD take-in that corresponds to the modern Clinical Guidelines. Prescribed daily doses of metformin (PDD) are significantly lower (by 34.71%) than the doses fixed by the WHO Centre. The second frequently prescribed drugs are sulfonylureas with gliclazide MB at the top. PDD of glimepiride and glibenclamide are considerably higher than DDD. DPP-4 medicines are quite often prescribed (up to 10.2% as a part of the combined therapy, including fixed combinations).

Conclusion.

The efficacy of antihyperglycemic therapy assessed upon achievement of HbA1c individual target in Omsk is 40.5%. Most patients with type 2 diabetes in the studied cohort have had the adequate antihypertensive therapy with reaching a target blood pressure in 75.8% of patients. Statin drugs are prescribed only in 39.3% of cases of dyslipidemia in type 2 diabetes, and only in 32.3% of them the targets of lipid metabolism parameters are achieved.

1. Дедов И.И., Шестакова М.В., Галстян Г.Р., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой (7-й выпуск). // Сахарный диабет. – 2015. – Т. 18. №1s. – С. 1-112 [Dedov II, Shestakova MV, Galstyan GR, et al. Standards of specialized diabetes care. Edited by Dedov II, Shestakova MV. (7-th edition). Diabetes mellitus. 2015;18(1s):1-112. (in russ.)]. doi. org/10.14341/dm20151s1-112.

2. Casagrande SS, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013;36(8):2271-2279. doi: 10.2337/dc12-2258.

3. Петров В.И. Клиническая фармакология и фармакотерапия в реальной врачебной практике. Мастер-класс. Учебник. – М.: ГЭОТАР-медиа; 2011 [Petrov VI. Clinical pharmacology and pharmacotherapy in real medical practice. The master class. Moscow: GEOTAR-media; 2011.] (in Russ.).

4. Guidelines for ATC classification and DDD assignment 18th edition. WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health; 2015. Available from:http://www.whocc.no/filearchive/publications/2015_guidelines.pdf

5. Калашникова М.Ф., Белоусов Д.Ю., Сунцов Ю.И., и др. Фармакоэпидемиологический анализ потребления сахароснижающих лекарственных средств у больных сахарным диабетом 2-го типа в Москве. // Сахарный диабет. – 2015. – Т. 18. – №2 – С. 32-46. [Kalashnikova MF, Belousov DY, Suntsov YI, et al. Pharmacoepidemiological and pharmacoeconomic analyses of the utilization of hypoglycaemic drugs in patients with type 2 diabetes mellitus in Moscow. Diabetes mellitus. 2015;18(2):32-46. (In Russ).]. doi: 10.14341/DM2015232-46.

6. Шведова А.М. Фармакоэпидемиологическая и фармакоэкономическая оценка пероральной сахароснижающей терапии сахарного диабета 2-го типа в амбулаторной практике. // Международный эндокринологический журнал. – 2007. – Т.4. – №10. Доступно по ссылке: http://www.mif-ua.com/archive/article/2875 [Shvedova AM. Pharmacoepidemiologic and pharmacoeconomic evaluation of oral hypoglycemic therapy of diabetes mellitus of the 2nd type in ambulatory practice. International journal of endocrinology. 2007;4(10). Available: http://www.mif-ua.com/archive/article/2875 (In Russ.)].

7. Ringborg A, Lindgren P, Martinell M, et al. Prevalence and incidence of type 2 diabetes and its complications 1996—2003-estimates from a Swedish population-based study. Diabet Med. 2008;25(10):1178-1186. doi: 10.1111/j.1464-5491.2008.02541.x.

8. Ringborg A, Lindgren P, Yin DD, et al. Time to insulin treatment and factors associated with insulin prescription in Swedish patients with type 2 diabetes. Diabetes Metab. 2010;36(3):198-203. doi: 10.1016/j.diabet.2009.11.006.